1. Gastro-Intestinal System | 2. Cardiovascular System | 3. Respiratory System | 4. Central Nervous System | 5. Antimicrobials | 6. Endocrine System | 7. Obstetrics, Gynaecology & Urology | 8. Malignant Disease & Immunosuppression | 9. Nutrition & Blood | 10. Musculoskelatal & Joint Diseases | 11. Opthalmology | 12. Ear, Nose & Oropharynx | 13. Dermatology | 14. Immunology & Vaccines | 15. Anaesthetics | GP Centre Home
Endocrine System
1. Antidiuretic hormone disorders | ||||||||||||||
1.1 Diabetes Insipidus | ||||||||||||||
PITUITARY & HYPOTHALAMIC HORMONES & ANALOGUES – Vasopressin & analogies | NOTES | |||||||||||||
DESMOPRESSIN | Tablets 100micrograms, 200 micrograms Nasal spray 10 micrograms Intranasal solution 100micrograms/ml Injection 4 micrograms in 1ml | Safety Alert – Risk of severe harm or death when desmopressin is witheld or omitted in patients with cranial diabetes insipidus APC Policy Statement Desmopressin for noctural polyuria APC Traffic light status: BLUE | ||||||||||||
VASOPRESSIN | Injection 20 units in 1ml | RESTRICTED : ITU CONSULTANT ONLY (Unlicensed Use) “For critically ill patients, within the ITU, with profound hypotension due to peripheral vasodilatation, eg septic shock/ severe infection or inflammation, in association with reduced responsiveness and effectiveness of usual catecholamine vasopressor therapy” Approved off-licence use – reducing blood loss during myomectomy. Restricted to Obs & Gynae Consultants only, Screening checklist must be completed and sent to pharmacy with prescription APC Traffic light status: none | ||||||||||||
1.1 Syndrome of inappropriate antidiuretic hormone secretion | ||||||||||||||
PITUITARY & HYPOTHALAMIC HORMONES & ANALOGUES – Vasopressin & analogies | NOTES | |||||||||||||
TOLVAPTAN (JINARC) | Tablets 15mg, 30mg, 60mg, 90mg | NICE Guidance Tolvaptan for treating autosomal dominant polycystic kidney disease [TA 358] APC Traffic light status: RED | ||||||||||||
ANTIDIURETIC HORMONE ANTAGONISTS | NOTES | |||||||||||||
DEMECLOCYCLINE | Capsules 150mg | Used in treatment of hyponatraemia resulting from SIADH APC Traffic light status: none | ||||||||||||
2 Corticosteroids | ||||||||||||||
GLUCOCORTICOID THERAPY | NOTES | |||||||||||||
Guidance |
WITHDRAWAL & GRADUAL TAPERING REQUIRED IN THE FOLLOWING: Provide Steroid treatment card, patient information leaflet and withdrawal/tapering guidance | |||||||||||||
BETAMETHASONE | Dispersible tablets 500micrograms Injection 4mg | APC Traffic light status: none | ||||||||||||
DEXAMETHASONE | Tablets 500micrograms, 2mg Injection 6.6mg/2ml (dexamethasone base) | Dexamethasone memo March 2017 APC Traffic light status: GREEN | ||||||||||||
FLUDROCORTISONE | Tablets 100micrograms | Very high mineralocorticoid activity. Insignificant glucocorticoid activity. APC Traffic light status: BLUE | ||||||||||||
HYDROCORTISONE | Tablets 10mg, 20mg | Adrenal insufficiency APC Traffic light status: BLUE | ||||||||||||
Tablets 10mg, 20mg | inflammatory conditionss APC Traffic light status: GREEN | |||||||||||||
Injection (sodium phosphate) 100mg, (sodium succinate) 100mg | ||||||||||||||
METHYLPREDNISOLONE | Tablets 2mg Injection (sodium succinate) 40mg, 500mg, 1g, 2g Injection (acetate) 40mg, 80mg, 120mg (IM depot) | APC Traffic light status: none | ||||||||||||
PREDNISOLONE | Tablets 1mg, 5mg, 25mg (restricted to oncology/haematology patients Soluble tablets 5mg | Soluble tablets restricted to paediatrics only Enteric coated tablets are non-formulary APC Traffic light status: GREEN | ||||||||||||
TRIAMCINOLONE ACETONIDE | Injection 40mg in 1ml, 50mg in 5ml | Rheumatic disease and intra-articular injection. ‘Black’ for allergic rhinitis/hayfever. Not on the formulary for this indication.APC Traffic light status: none | ||||||||||||
2.1 Cushing’s syndrome and disease | ||||||||||||||
ENZYME INHIBITORS | NOTES | |||||||||||||
METYRAPONE | Capsules 250mg | APC Traffic light status: none | ||||||||||||
3 Diabetes Mellitus and hypoglycaemia | ||||||||||||||
3.1 Diabetes Mellitus | ||||||||||||||
SURREY CCG DIABETES PATHWAY | CCG Type 2 Diabetes Prescribing Guidelines | |||||||||||||
BLOOD GLUCOSE LOWERING DRUGS – Biguanides | NOTES | |||||||||||||
METFORMIN | Tablets 500mg, 850mg SR Tablets 500mg, 750mg, 1g Liquid 500mg in 5ml (restricted to enteral tubes and patients unable to swallow tablets) | APC Traffic light status: GREEN | ||||||||||||
BLOOD GLUCOSE LOWERING DRUGS – Dipeptidylpeptidase-4 inhibitors (gliptins) | NOTES | |||||||||||||
LINAGLIPTIN | Tablets 5mg | RESTRICTED Use : DIABETES TEAM ONLY NICE CG New Diabetes AgentsAPC Traffic light status: GREEN | ||||||||||||
SITAGLIPTIN | Tablets 100mg | RESTRICTED Use : DIABETES TEAM ONLY NICE CG New Diabetes AgentsAPC Traffic light status: GREEN | ||||||||||||
BLOOD GLUCOSE LOWERING DRUGS – Glucagon-like-peptide-4 receptor agonists | NOTES | |||||||||||||
DULAGLUTIDE | Injection (Trucility) PF pen | RESTRICTED Use: DIABETES INITIATION ONLY PCN Dulaglutide APC Traffic light status: GREEN | ||||||||||||
EXENATIDE | PF pen (Byetta) 5micrograms, 10micrograms Injection (Bydureon) 2mg vial, 2mg pen – once weekly administration | RESTRICTED Use : DIABETES INITIATION ONLY NICE CG New Diabetes Agents NICE TAG BydureonAPC Traffic light status: GREEN | ||||||||||||
LIRAGLUTIDE | PF pen 6mg/ml, 3ml | RESTRICTED Use : DIABETES INITIATION ONLY NICE TA 203: LiraglutideNote: Liraglutide is consider ‘BLACK’ by APC for use in weight management and is not on the formulary for this indication.APC Policy statement: Liraglutide (Saxenda) for weight managementAPC Traffic light status: GREEN | ||||||||||||
LIXISENATIDE | PF Pen 10micrograms, 20 micrograms | RESTRICTED Use : DIABETES INITIATION ONLY NICE CG New Diabetes Agents NICE Lixisenatide ESNM PCN Lixisenatide APC Traffic light status: GREEN | ||||||||||||
BLOOD GLUCOSE LOWERING DRUGS – Meglitinides | NOTES | |||||||||||||
NATEGLINIDE | Tablets 60mg | RESTRICTED Use : DIABETES TEAM ONLY APC Traffic light status: none | ||||||||||||
BLOOD GLUCOSE LOWERING DRUGS – Sodium glucose co-transporter 2 inhibitors | NOTES | |||||||||||||
NICE Guidance | NICE Guidance Canagliflozin, Dapagliflozin and Empagliflozin as monotherapies for treating Type 2 Diabetes | |||||||||||||
CANAGLIFLOZIN | Tablets 100mg, 300mg | RESTRICTED Use: DIABETES INITIATION ONLY NICE TAG CanagliflozinPCN Policy StatementDrug Safety Update March 2017 – updated advice on increased risk of lower limb amputation (mainly toes)APC Traffic light status: GREEN | ||||||||||||
DAPAGLIFLOZIN | Tablets 5mg, 10mg | RESTRICTED Use: DIABETES INITIATION ONLY
NICE TA597: Dapagliflozin with insulin for treating type 1 diabetes APC Policy Statement 2013: Dapagliflozin in Type 2 Diabetes APC Traffic light status: GREEN | ||||||||||||
Tablets 5mg, 10mg | RESTRICTED Use: DIABETES INITIATION ONLY Refer to shared care guideline. Minimum of 3 months prescribing by specialist before transfer of prescribing can be requested. NICE TA597: Dapagliflozin with insulin for treating type 1 diabetes APC Policy Statement 2019: Dapagliflozin in Type 1 DiabetesAPC Traffic light status: AMBER | |||||||||||||
EMPAGLIFLOZIN | Tablets 10mg, 25mg | RESTRICTED Use: DIABETES INITIATION ONLY NICE EmpagliflozinAPC Traffic light status: GREEN | ||||||||||||
ERTUGLIFLOZIN | 5mg, 15mg tablets | RESTRICTED Use: DIABETES INITIATION ONLY NICE TA 572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes APC Traffic light status: GREEN | ||||||||||||
SOTAGLIFLOZIN | 200mg | RESTRICTED Use: DIABETES INITIATION ONLY NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes Sotagliflozin is not yet available in the NHS, but the company anticipates that it will be available to the NHS in England and Wales within 12 months of NICE guidance publication (Feb 2020). | ||||||||||||
BLOOD GLUCOSE LOWERING DRUGS – Sulphonylureas | NOTES | |||||||||||||
GLICLAZIDE | Tablets 40mg, 80mg | APC Traffic light status: GREEN | ||||||||||||
MR 30mg | (MR restricted use; diabetes team only) APC Traffic light status: not preferred | |||||||||||||
GLIMEPIRIDE | Tablets 1mg, 3mg | APC Traffic light status: none | ||||||||||||
GLIPIZIDE | Tablets 2.5mg, 5mg | APC Traffic light status: none | ||||||||||||
BLOOD GLUCOSE LOWERING DRUGS – Thiazolidinediones | NOTES | |||||||||||||
PIOGLITIZONE | Tablets 30mg, 45mg | RESTRICTED Use : DIABETES TEAM ONLY NICE CG New Diabetes Agents APC Traffic light status: GREEN | ||||||||||||
PIOGLITAZONE/METFORMIN | Tablets | |||||||||||||
INSULINS | ||||||||||||||
Guidance | For patients coming in on NonFormularyDrug (NFD) Insulins wherever possible, use patients own drugs. NFD INSULINS can be ordered to prevent patients destabilising their usual insulin therapy | |||||||||||||
INSULINS – Short acting | NOTES | |||||||||||||
SOLUBLE INSULIN | Hypurin (porcine neutral) 100units/ml vial | APC Traffic light status: none | ||||||||||||
Actrapid 100units/ml vial | APC Traffic light status: none | |||||||||||||
INSULIN ASPART | Novorapid® flexpens, penfill, vial | APC Traffic light status: GREEN | ||||||||||||
Fiasp® flexpens, penfill, vial | Fiasp® RESRICTED Use to DIABETES TEAM ONLY Fiasp for treating Diabetes Mellitus PCN Policy Statement APC Traffic light status: BLUE | |||||||||||||
INSULIN GLULISINE | Apidra® Solostar pen | RESTRICTED Use DIABETES TEAM ONLY APC Traffic light status: GREEN | ||||||||||||
INSULIN LISPRO | Humalog® kwikpen, cartridges | APC Traffic light status: GREEN | ||||||||||||
INSULINS – Intermediate acting | NOTES | |||||||||||||
BIPHASIC ISOPHANE | Humulin M3 cartridges, Kwikpen | APC Traffic light status: none | ||||||||||||
ISOPHANE INSULIN | Insulatard® cartridges, Innolet, | APC Traffic light status: none | ||||||||||||
Insuman®Basal Solostar pen | APC Traffic light status: none | |||||||||||||
BIPHASIC ASPART | Novomix® 30 flexpen, cartridges, vial | APC Traffic light status: GREEN | ||||||||||||
BIPHASIC LISPRO | Humalog® Mix 25 cartridges, Kwikpen | APC Traffic light status: GREEN | ||||||||||||
Humalog ® Mix 50 Kwikpen | APC Traffic light status: GREEN | |||||||||||||
INSULINS – Long acting | NOTES | |||||||||||||
INSULIN DEGLUDEC | Tresiba® 100 units/ml, 200 units/ml pre-filled pen Tresiba® 100units/ml catridges | RESTRICTED USE: DIABETES TEAM ONLY
Tresiba® cartridges for prescribing in out-patients APC Traffic light status: BLUE | ||||||||||||
INSULIN DETEMIR | Levemir® flexpen, Innolet, cartridges | RESTRICTED USE: DIABETES TEAM ONLY APC Traffic light status: GREEN | ||||||||||||
INSULIN GLARGINE | Lantus® Cartridges, Solostar pens | RESTRICTED USE: DIABETES TEAM ONLY NICE Guidance on Insulin Glargine (2002)APC Traffic light status: GREEN | ||||||||||||
INSULIN GLARGINE | Toujeo ® 300 units /ml pre-filled pen | RESTRICTED USE: DIABETES TEAM ONLY APC Traffic light status: BLUE | ||||||||||||
3.2 Hypoglycaemia | ||||||||||||||
GLYCOGENOLYTIC HORMONES | ||||||||||||||
GLUCAGON | 1mg powder for injection (pre-filled syringe) | Used for acute hypoglycaemia APC Traffic light status: none | ||||||||||||
GLUCOSE | ||||||||||||||
GLUCOGEL | Oral dextrose 40% gel | Used for acute hypoglycaemia APC Traffic light status: none | ||||||||||||
GLUCOSE | 10 % Injection (10ml) 25 % Injection (25ml) 50 % Injection (50ml) | Also used in lower UTI & prostatitis APC Traffic light status: none | ||||||||||||
3.2a Chronic Hypoglycaemia | ||||||||||||||
GLYCOGENOLYTIC HORMONES | ||||||||||||||
DIAZOXIDE | Liquid 50mg in 1ml | Paediatrics Only APC Traffic light status: none | ||||||||||||
4 Disorders of bone metabolism | ||||||||||||||
BISPHOSPHONATES | ||||||||||||||
Guidance | PCN Osteoporosis Treatment Pathway for Adults Algorithm 1 | |||||||||||||
ALENDRONIC ACID | Tablets 10mg (daily) Tablets 70mg (weekly) Solution 70mg in 100ml | Joint 1st line agent Solution suitable for patients with swallowing difficultiesPCN Policy Statement – Alendronate solutionAPC Traffic light status: GREEN | ||||||||||||
IBANDRONIC ACID | Tablets 150mg Injection 3mg in 3ml
| SMC Guidance RESTRICTED USE Consultant RHEUMATOLOGIST/ CARE of ELDERLY Only. APC Traffic light status: GREEN | ||||||||||||
PAMIDRONATE DISODIUM | Injection 5mg in 5ml | APC Traffic light status: RED | ||||||||||||
RISEDRONATE SODIUM | Tablets 5mg (daily) Tablets 30mg , 35mg (weekly) | Joint 1st line agent (ALENDRONATE is also 1st line) 30mg tablet for Pagets disease of bone APC Traffic light status: GREEN | ||||||||||||
SODIUM CLODRONATE | Capsules 400mg, Tablets 520mg | APC Traffic light status: none | ||||||||||||
ZOLEDRONIC ACID (ZOMETA) | Injection 4mg in 5ml | RESTRICTED USE In malignancy & multiple myeloma patients only SWISH Ca Network ApprovedAPC Traffic light status: RED | ||||||||||||
ZOLEDRONIC ACID (ACLASTA) | Injection 50micrograms/ml | RESTRICTED USE Rheumatology & Orthogeriatrics GuidelinesAPC Traffic light status: RED | ||||||||||||
CALCIUM REGULATING DRUGS – Bone resorption inhibitors | ||||||||||||||
CALCITONIN (Salmon) | Injection 100 units in 1ml, 400 units in 2ml | APC Traffic light status: none | ||||||||||||
CALCIUM REGULATING DRUGS – Parathyroid hormones and analogies | ||||||||||||||
TERIPARATIDE | Injection 250micrograms/ml | RESTRICTED USE: Consultant RHEUMATOLOGIST OnlyNICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women APC 2019 Policy Statement – Teriparatide biosimilar APC Traffic light status: RED | ||||||||||||
CALCIUM REGULATING DRUGS – Monoclonal antibodies | ||||||||||||||
DENOSUMAB (PROLIA) | Pre-filled syringe 60mg/ml | RESTRICTED USE Rheumatology & Orthogeriatrics NICE TAG Denosumab SASH_CCG DENOSUMAB [Green] SASH_CCG Denosumab Rx Information APC Traffic light status: GREEN | ||||||||||||
DENOSUMAB (XGEVA) | Vial 120mg | RESTRICTED USE For solid tumour patients with bone metastases NOT approved for patients with prostate cancer SWISH Ca Network Approval NICE TA 265APC Traffic light status: RED | ||||||||||||
5 Dopamine responsive conditions | ||||||||||||||
QUINAGOLIDE | Starter pack tablets, 75 micrograms | APC Traffic light status: none | ||||||||||||
6 Gonadotrophin responsive conditions | ||||||||||||||
PITUITARY & HYPOTHALAMIC HORMONES & ANALOGUES – Gonadotropin-releasing hormones | NOTES | |||||||||||||
Guidance | Gonadorelin analogues used in treatment of endometriosis, precocious puberty, infertility, breast cancer and prostate cancer. | |||||||||||||
BUSERELIN | 150micrograms/dose nasal spray 1mg/ml vial for injection | APC Traffic light status: none | ||||||||||||
GOSERELIN | Zoladex 3.6mg implant | S/C Injection every 4 weeks Prostate cancer APC Traffic light status: BLUE Infertility APC Traffic light status: RED | ||||||||||||
LEUPRORELIN ACETATE | Prostap SR 3.75mg | S/C or IM injection every 4 weeks Prostate cancer APC Traffic light status: BLUE | ||||||||||||
NAFARELIN | 200 microgram Nasal Spray (Synarel) | Infertility APC Traffic light status: RED | ||||||||||||
TRIPTORELIN | 3.75 mg Injection Injection (Gonapeptyl Depot) | S/C or IM injection : dose dependant on clinical indication Prostate cancer APC Traffic light status: BLUE Precocious puberty APC Traffic light status: AMBER | ||||||||||||
6.1 Hereditary angiodema | ||||||||||||||
PITUITARY & HYPOTHALAMIC HORMONES & ANALOGUES – Anti-gonadotropin-releasing hormones | NOTES | |||||||||||||
DANAZOL | Capsules 200mg | APC Traffic light status: none | ||||||||||||
7 Hypothalamic & anterior pituitary hormone related disorders | ||||||||||||||
7.1 Adrenocortical function testing | ||||||||||||||
PITUITARY & HYPOTHALAMIC HORMONES & ANALOGUES – Corticotrophins | NOTES | |||||||||||||
TETRACOSACTIDE | Injection 250micrograms in 1ml Injection (Depot) 1mg in 1ml | APC Traffic light status: none | ||||||||||||
7.3 Gonadotrophin replacement therapy | ||||||||||||||
GONADOTROPHINS | NOTES | |||||||||||||
CHORIONIC GONADOTROPHIN | (CHORAGON) 5000 units Injection (BREVACTID) 1500 units vials | Specialist prescribing only Induction of spermatogenenis in men with hypogonadism who desire fertility (following Pregnyl discontinuation). Endocrine testing: 3 week HCG test Brevactid is unlicensed product. To prescribe when other products are unavailable. Note: Pregnyl discontinued. APC Traffic light status: none | ||||||||||||
MENOTROPHIN | (MENOPUR) 75 units Injection (MERIONAL) 75 units Injection (MENOGON) 75 units Injection | APC Traffic light status: none | ||||||||||||
7.4 Growth hormone disorders | ||||||||||||||
PITUITARY & HYPOTHALAMIC HORMONES & ANALOGUES – Human growth hormones | NOTES | |||||||||||||
SOMATROPIN | Injection 12mg (36 units) (Genotropin) Refill Cartridge SimpleXx Refill Injection 15mg (45 units) (Norditropin) MiniQuick Injection 0.4mg (1.2 units), 1.2mg (3.6units)(Genotropin) Syringe | Growth failure adults & children APC Traffic light status: AMBER | ||||||||||||
8 Sex hormone responsive conditions | ||||||||||||||
8.1 Female sex hormone responsive conditions | ||||||||||||||
CALCIUM RELATING DURGS – bone resorption inhibitors | NOTES | |||||||||||||
Raloxifene | 60mg Tablet | NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women Osteoporosis APC Traffic light status: GREEN | ||||||||||||
OESTROGENS | NOTES | |||||||||||||
CSM – REASONS TO STOP HRT severe chest pain, sudden breathlessness, severe calf pain or stomach painneurological effects (prolonged headache/epileptic seizure/loss of vision/marked numbness)hepatitis/jaundice, severe depression, BP>160/100CSM – risk of breast cancer with HRT CSM – risk of venous thromboembolism with HRT CSM – risk of endometrial and ovarian cancer with HRT CSM – risk of stroke and possibly coronary disease with HRTMHRA WARNING | ||||||||||||||
CONJUGATED OESTROGENS (equine) | PREMARIN 625 microgram Tablets | HRT APC Traffic light status: GREEN | ||||||||||||
ESTRADIOL | 2mg Tablets (ESTRADERM MX) 50 microgram Patches EVOREL 25, 50 & 100 Patches FEMSEVEN 50 microgram in 24hr Patches | HRT APC Traffic light status: GREEN | ||||||||||||
ETHINYLESTRADIOL | Tablets 10micrograms, 50 micrograms & 1mg | HRT APC Traffic light status: GREEN | ||||||||||||
TIBOLONE | 2.5 mg Tablets | HRT APC Traffic light status: GREEN | ||||||||||||
ESTRADIOL + NORETHISTERONE | EVOREL CONTI Patches CLIMAGEST 2mg Tablets KLIOVANCE Tablets TRISEQUENS Tablets | HRT APC Traffic light status: GREEN | ||||||||||||
ESTRADIOL + NORGESTREL | CYCLO-PROGYNOVA 2 mg Tablets | APC Traffic light status: none | ||||||||||||
CONJUGATED OESTROGENS + MEDROXYPROGESTERONE | PREMIQUE Tablets | HRT APC Traffic light status: GREEN | ||||||||||||
PROGESTOGENS | NOTES | |||||||||||||
MEDROXYPROGESTERONE | Tablets 5mg, 10mg | APC Traffic light status: none | ||||||||||||
NORETHISTERONE | Tablets 1mg, 5mg | APC Traffic light status: none | ||||||||||||
PROGESTERONE | Pessaries 200mg, 400mg Injection 50mg in 1ml, 100mg in 2ml | APC Traffic light status: none | ||||||||||||
8.1a Anti-oestrogens | ||||||||||||||
CLOMIFENE | Tablets 50mg | Infertility APC Traffic light status: RED | ||||||||||||
8.2 Male sex hormone responsive conditions | ||||||||||||||
TESTOSTERONE | Testosterone Decanoate Injection (Sustanon 250) Undecanoate capsules 40mg 2% gel 10mg/application (Tostran) Implant 100mg, 200mg | male hypogonadism APC Traffic light status: BLUE low libido in women APC Traffic light status: BLUE | ||||||||||||
9 Thyroid disorders | ||||||||||||||
PROTIRELIN | 200 micrograms in 2ml Injection | APC Traffic light status: none | ||||||||||||
9.1 Hyperthyroidism | ||||||||||||||
ANTITHYROID DRUGS | NOTES | |||||||||||||
CARBIMAZOLE | Tablets 5mg, 20mg | CSM WARNING Observe for NEUTROPENIA & AGRANULOCYTOSIS Monitor for signs of infection & blood cell count.Hyperthyroidism APC Traffic light status: GREEN | ||||||||||||
PROPYLTHIOURACIL | Tablets 50mg | Hyperthyroidism APC Traffic light status: GREEN | ||||||||||||
IODINE | (Lugol’s Oral Solution) Iodine 5%, potassium iodide 10% | Visualisation in Surgery / Diagnostics Total Iodine 130mg/ml APC Traffic light status: none | ||||||||||||
9.2 Hypothyroidism | ||||||||||||||
LEVOTHYROXINE SODIUM | Tablets 25micrograms, 50micrograms, 100micrograms | UKMi Interaction between Orlistat & Thyroxine Hypothyrodism APC Traffic light status: GREEN | ||||||||||||
LIOTHYRONINE | Tablet 20micrograms | Hypothyroidism with inadequate response or intolerance to levothyroxine APC Traffic light status: AMBER Liothyronine MONOTHERAPY Amber shared care guidelines – Dec 2019 Shared Care Agreement Communication Form | ||||||||||||
Monotherapy in oncology – thyroid and parathyroid disease APC Traffic light status: RED APC statement: Liothyronine in oncology Thyrotoxicosis APC Traffic light status: RED APC policy statement – Liothyronine for thyrotoxicosis – June 2019Depression APC Traffic light status: RED APC policy statement – Liothyronine for depression – June 2019 | ||||||||||||||
Injection 20micrograms | More rapid onset of action than levothyroxine In hypothyroid coma though always check for adrenal sufficiencyComa of Myxoedema APC Traffic light status: REDAPC policy statement – Liothyronine myxoedema coma – June 2019 |
1. Gastro-Intestinal System | 2. Cardiovascular System | 3. Respiratory System | 4. Central Nervous System | 5. Antimicrobials | 6. Endocrine System | 7. Obstetrics, Gynaecology & Urology | 8. Malignant Disease & Immunosuppression | 9. Nutrition & Blood | 10. Musculoskelatal & Joint Diseases | 11. Opthalmology | 12. Ear, Nose & Oropharynx | 13. Dermatology | 14. Immunology & Vaccines | 15. Anaesthetics | GP Centre Home